Cue Biopharma (CUE) Research Hub

Cue Biopharma (CUE) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 18.45 USD (-1.13%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -6.20, market cap 0.09B. This hub links to the full technical, earnings and options research available for CUE.

Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ

SectorHealthcare (Biotechnology)
ExchangeNASDAQ, US
Last close18.45 USD (-1.13%)
52-week range15.93 USD – 41.5 USD
Trend regimeRange
14-day RSI39 (Bearish)
Trailing P/E-6.20
Market cap0.09B
Dividend yield0.00%
Next earnings2026-08-18

Available research for CUE

Earnings

CUE earnings date and last-quarter result: next report 2026-08-18, last quarter beat, P/E -6.20. Updated 2026-07-23.

Options: Covered Call

Covered Call on CUE: how it works, illustrative setup around the real 18.45 USD price, max profit/loss, breakeven and when to use it. Educational.

Options: Iron Condor

Iron Condor on CUE: how it works, illustrative setup around the real 18.45 USD price, max profit/loss, breakeven and when to use it. Educational.

Options: Protective Put

Protective Put on CUE: how it works, illustrative setup around the real 18.45 USD price, max profit/loss, breakeven and when to use it. Educational.

Technical

CUE technical analysis: range, last 18.45 USD, RSI 39, 52w range 15.93 USD–41.5 USD, real support/resistance. Updated 2026-10-26.

More on SniperIQ

Frequently asked questions

What sector is CUE in?

Cue Biopharma (CUE) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.

Is CUE in an uptrend or downtrend?

As of 2026-10-26, CUE is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.

What is CUE's trailing P/E ratio?

CUE's trailing P/E is -6.20, with a market cap of 0.09B. See the earnings research page for full valuation detail.

When does CUE next report earnings?

CUE is next scheduled to report earnings on 2026-08-18.